Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib in Mild to Moderate Alzheimer's Disease
NCT02947893Phase 2Completed
- Sponsor
- Georgetown University
- Start
- Jan 2017
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nilotinib in Alzheimer's disease (AD) (2 arms), sponsored by Georgetown University. Primary endpoint: Safety and tolerability (Adverse Events and Abnormal Laboratory Values) at 12 months. Started Jan 2017; status: completed.
02
Drugs
nilotinib
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02947893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02947893.